- Home
- HRMY vs SPNS Comparison
HRMY vs SPNS Comparison
Compare HRMY & SPNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SPNS
- Stock Information
- Founded
- HRMY 2017
- SPNS 1982
- Country
- HRMY United States
- SPNS Israel
- Employees
- HRMY N/A
- SPNS N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SPNS Computer Software: Prepackaged Software
- Sector
- HRMY Health Care
- SPNS Technology
- Exchange
- HRMY Nasdaq
- SPNS Nasdaq
- Market Cap
- HRMY 1.8B
- SPNS 1.6B
- IPO Year
- HRMY 2020
- SPNS 1992
- Fundamental
- Price
- HRMY $34.00
- SPNS $29.51
- Analyst Decision
- HRMY Strong Buy
- SPNS Buy
- Analyst Count
- HRMY 9
- SPNS 4
- Target Price
- HRMY $54.44
- SPNS $34.25
- AVG Volume (30 Days)
- HRMY 642.5K
- SPNS 159.8K
- Earning Date
- HRMY 08-05-2025
- SPNS 07-31-2025
- Dividend Yield
- HRMY N/A
- SPNS 2.03%
- EPS Growth
- HRMY 13.13
- SPNS 11.11
- EPS
- HRMY 2.62
- SPNS 1.30
- Revenue
- HRMY $744,852,000.00
- SPNS $544,235,000.00
- Revenue This Year
- HRMY $20.10
- SPNS $8.30
- Revenue Next Year
- HRMY $18.01
- SPNS $7.42
- P/E Ratio
- HRMY $13.10
- SPNS $23.09
- Revenue Growth
- HRMY 20.62
- SPNS 3.84
- 52 Week Low
- HRMY $26.47
- SPNS $23.69
- 52 Week High
- HRMY $41.61
- SPNS $41.22
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- SPNS 53.39
- Support Level
- HRMY $31.70
- SPNS $29.50
- Resistance Level
- HRMY $35.08
- SPNS $30.54
- Average True Range (ATR)
- HRMY 0.95
- SPNS 0.51
- MACD
- HRMY 0.27
- SPNS 0.05
- Stochastic Oscillator
- HRMY 71.80
- SPNS 57.26
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SPNS Sapiens International Corporation N.V. (Cayman Islands)
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.